Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023
Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023
CAMBRIDGE, MA / ACCESSWIRE / March 24, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will present its Vaccines Day for analysts and investors at 8:00 a.m. ET on Tuesday, April 11, 2023.
Moderna's Vaccines Day will include presentations from management and key opinion leaders (KOLs) on Moderna's mRNA vaccines and key considerations for vaccine development. A live webcast will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for one year following the presentation.
About Moderna
In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio and integrated manufacturing facilities that allow for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID pandemic.
Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past eight years. To learn more, visit
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View source version on accesswire.com:
CAMBRIDGE, MA / ACCESSWIRE / March 24, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will present its Vaccines Day for analysts and investors at 8:00 a.m. ET on Tuesday, April 11, 2023.
麻薩諸塞州劍橋/交通線材 /2023 年 3 月 24 日/ 現代公司（NASDAQ：MRNA）是一家開創信使 RNA（mRNA）治療和疫苗的生物技術公司，今天宣布，該公司將於 2023 年 4 月 11 日（星期二）早上 8 點向分析師和投資者展示疫苗日。
Moderna's Vaccines Day will include presentations from management and key opinion leaders (KOLs) on Moderna's mRNA vaccines and key considerations for vaccine development. A live webcast will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for one year following the presentation.
Moderna 的疫苗日將包括管理層和關鍵意見領袖（KOL）就 Moderna 的 mRNA 疫苗以及疫苗開發的關鍵考慮因素的演講。現場直播將在 Moderna 網站投資者部分的「活動和演示文稿」下提供，網上直播是投資者 .modernatx.com。簡報後，網路廣播的重播將存放在 Moderna 的網站上，為期一年。
About Moderna
關於摩德納
In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio and integrated manufacturing facilities that allow for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID pandemic.
Moderna 成立以來 10 多年來，已從一家研究階段的公司，在 Messenger RNA (mRNA) 領域推進專案，轉變為擁有七種模式多樣化臨床疫苗和治療產品組合的企業、廣泛的智慧財產產權組合以及可大規模快速臨床和商業生產的綜合製造設施。Moderna 與廣泛的國內和海外政府和商業合作夥伴保持聯盟，這使得追求突破性的科學和製造業的快速擴展。最近，Moderna 的能力匯集在一起，允許對抗 COVID 大流行的最早，最有效的疫苗之一的授權使用和批准。
Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past eight years. To learn more, visit
Moderna 的 mRNA 平台建立在基礎和應用 mRNA 科學、傳遞技術和製造方面的持續進步，並允許開發用於傳染病、免疫腫瘤、罕見疾病、心血管疾病和自身免疫性疾病的治療和疫苗。莫德納（Moderna）在過去八年中被 Science 評為頂級生物製藥雇主。要了解更多信息，請訪問
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
投資者：
拉维纳-塔卢克达尔
資深副總裁兼投資者關係主管
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
來源： 莫德纳公司
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧